Activation of abnormal splicing may activate cancer-promoting functions through input in several biological processes leading to the initiation and proliferation of carcinogenic cells, tumor development, drug resistance, etc. A group of splicing modulators particularly targeting SF3b complex (or its PHF5A component) are illustrated to display cytotoxic activity against cancer cells and might be considered potential therapeutic targets for the management of cancer [29]. Here, PHF5A is linked to cancer.